Swarm was formed in 2022 and has now emerged with Martin Olin – previously chief executive of BerGenBio and Symphogen – at ...

Chinese biotech Ascentage Pharma has taken the first US biotech initial public offering (IPO) of 2025 over the finish line, ...

Evolution and innovation are critical to the field of life sciences, with each year bringing new challenges and breakthroughs ...

The pharma group has pledged up to £50 million ($62.5 million) in funding over three years for the initiative, which builds ...

Pfizer has agreed to pay $60 million to resolve allegations brought by the US government that its Biohaven Pharma subsidiary ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

Drug development is a high-stakes, high-cost endeavour. Every new drug entering clinical trials requires careful decision-making, particularly regarding trial design and resource allocation.

Verona Pharma has blockbuster hopes for its recently approved drug for chronic obstructive pulmonary disorder (COPD), and preliminary sales figures for the drug suggest it is heading in the right ...

Biogen says it is the first drugmaker in the US to get FDA approval for a biosimilar of Roche’s $3 billion blockbuster product Actemra. The intravenous biosimilar of IL-6 inhibitor Actemra ...

Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making versions of one of its GLP-1 agonist drugs. The latest attempt focuses ...

Veeva Systems’ Commercial Summit returned to Madrid for 2023, with over 1,500 life sciences industry professionals in attendance. Once more located at the Madrid Auditorium Hotel, the day kicked ...

With the Federal Reserve poised to implement interest rate cuts (albeit fewer than earlier forecasts assumed) and FTC leadership turnover anticipated, there may be broader shifts in how capital is ...